Navigation Links
Pfizer Enters Into Agreement to Acquire 40 Percent Stake in Teuto in Brazil
Date:10/20/2010

NEW YORK, Oct. 20 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) announced today that it is entering into a partnership with Laboratorio Teuto Brasileiro S.A., a leading company in the Brazilian generics industry, to develop and commercialize generic medicines.  Pfizer will acquire a 40 percent stake in Teuto and the companies will also enter into a series of commercial agreements.  The partnership will enhance Pfizer's position in Brazil, a key emerging market, by providing access to Teuto's broad portfolio of approximately 250 products in more than 400 presentations.  Through this partnership, Pfizer will have access to significant distribution networks in rural and suburban areas in Brazil and the opportunity to register and commercialize Teuto's products in various markets outside Brazil.  In addition, Pfizer will have two representatives on Teuto's board of directors.

(Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20100416/PFIZERLOGO)

Under the terms of the agreement, Pfizer will make an upfront payment of R$400 million (approximately US$240 million) and Teuto will be eligible to receive a performance-based milestone payment.  Pfizer has an option to acquire the remaining 60 percent of Teuto's shares beginning in 2014.  Teuto's shareholders have an option to sell their 60 percent stake to Pfizer beginning in 2015.

Pfizer will have the opportunity to register and commercialize Teuto products in Brazil and various markets outside of the country under its own brands, including branded and unbranded generic medicines, covering a broad range of therapeutic areas, such as pain and inflammation, cardiovascular, anti-infectives, central nervous system and respiratory, among others.  Teuto will gain access to select Pfizer products for distribution across its extensive distribution network and have the right to commercialize them under Teuto's own brand in Brazil.

In 2008, the global generics marketplace represented US$750 billion and is anticipated to grow up to US$920 billion by 2013, with the bulk of this growth generated in emerging markets. Today, branded and unbranded generics account for approximately 60 percent of the value of the Brazilian retail pharmaceutical market fueled by the increased purchasing power of growing middle and lower-middle income patients.

"We believe this partnership will enable both companies to effectively build upon one another's core capabilities and areas of expertise to help address the needs of more patients than ever before," said Jean-Michel Halfon, president of Pfizer's Emerging Markets Business Unit.  "This agreement demonstrates Pfizer's commitment to pursue focused investments in key emerging markets to accelerate our growth and increase patient access to high-quality medicines."

"Teuto's partnership with Pfizer is very complementary to our business goals.  It will expand our product portfolio and address the needs of the changing customer base," said Marcelo Henriques, chief executive officer of Teuto Laboratories.

The stake in Teuto demonstrates Pfizer's commitment to continue its expansion in emerging markets through customer-focused efforts by increasing access and affordability, partnering with other companies that offer diverse areas of expertise and leveraging the company's capabilities to build upon local markets.  

The transaction is subject to customary closing conditions and is expected to close by the end of fourth-quarter 2010.

Pfizer's financial advisor for the transaction was Goldman Sachs Group, Inc. while Skadden, Arps, Slate, Meagher & Flom LLP and Pinheiro Neto Advogados were its legal advisors.  Banco BTG Pactual SA served as Teuto's financial advisor, while Machado, Meyer, Sendacz & Opice and Cleary Gottlieb served as legal advisors.

Pfizer Inc.:  Working together for a healthier world™

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life.  We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals.  Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products.  Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.  Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world.  For more than 150 years, Pfizer has worked to make a difference for all who rely on us.  To learn more about our commitments, please visit us at www.pfizer.com.

About Pfizer Emerging Markets

Pfizer's Emerging Markets Business Unit was established in 2009 to meet the diverse medical needs of patients in emerging markets around the world in an innovative, socially responsible and commercially viable manner.  The unit is focused on three strategic priorities: investing in core brands, expansion in the generic market space and leveraging Pfizer's global capabilities to strengthen local markets.  Pfizer Emerging Markets spans more than 70 countries, across 20 time zones with over 19,000 colleagues and the potential to reach approximately 5 billion people.  The business unit has identified six priority markets – China, India, Brazil, Russia, Turkey and Mexico.

DISCLOSURE NOTICE: The information contained in this release is as of October 20, 2010. The Company assumes no obligation to update forward-looking statements contained in this release as a result of new information or future events or developments.

This release contains forward-looking information about an agreement by Pfizer to acquire a 40% stake in Teuto Laboratories (Teuto), commercial agreements to be entered into between Pfizer and Teuto, and the potential benefits of the proposed transaction. Such information involves substantial risks and uncertainties including, among other things, the satisfaction of conditions to closing the agreements; Pfizer's ability to successfully commercialize the products covered by the agreements; decisions by regulatory authorities regarding whether and when to approve any drug applications that may be filed for such products as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such products; and competitive developments.

A further list and description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.


'/>"/>
SOURCE Pfizer Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
2. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
3. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
4. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
5. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
6. Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
7. MannKind Addresses Pfizers Announcement Regarding Exubera
8. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
9. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
10. Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
11. Pfizer Contributes Critical Data to URMC Drug Safety Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)...  Endo International plc (NASDAQ: ENDP ) ... all known U.S. mesh product liability claims and that ... remaining U.S. claims at reasonable values. Under the agreements, ... quarter of 2017 and continuing through the fourth quarter ... results, the Company intends to increase its mesh product ...
(Date:8/2/2017)... AROMAS, Calif. , Aug. 2, 2017 /PRNewswire/ ... by Continental Who,s Who as a Pinnacle Lifetime ... currently the Key Account Manager at Turing Pharmaceuticals, ... communications, negotiations, troubleshooting and relationship building.                ... has more than 25 years of experience ...
(Date:8/1/2017)... Aug. 1, 2017   CerSci Therapeutics , a ... Texas , has received notice from the National ... of Health (NIH) that it has been awarded a ... over $650,000 in 2017 with an additional $1,000,000 to ... New Drug application of their lead non-opioid drug candidate ...
Breaking Medicine Technology:
(Date:8/18/2017)... ... August 18, 2017 , ... ... specialized asset-light logistics provider of complex transport solutions for mission-critical and non-discretionary ... Unitrans International Corporation, a division of Roadrunner Transportation Systems, Inc. (NYSE: RRTS). ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... devices. Through an educational webinar, they will present the line of epMotion automated ... learn how easy you can automate everyday pipetting tasks. , Ideal for scientists ...
(Date:8/18/2017)... Woodlands, TX (PRWEB) , ... August 18, 2017 ... ... protection assistance and financial planning services to communities in east Texas, is launching ... Pediatric Brain Tumor Foundation. , Founded in 1991, the Pediatric Brain Tumor Foundation ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... The Golseth ... in the Dallas/Fort Worth area, is spearheading a regional charity campaign organized to provide ... , In early June of this year, Christina and her children returned from out ...
(Date:8/18/2017)... ... August 18, 2017 , ... Alcovit, a lime-flavored beverage that rids the body ... with its product now available through Jet.com. , After 25 years of development, ... drink is designed to quickly detox the body thereby avoiding alcohol-induced hangovers. Whether you’re ...
Breaking Medicine News(10 mins):